Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

By E. Lewis, L. Hunsicker, W. Clarke, T. Berl, M. Pohl, J. Lewis, E. Ritz, R. Atkins, R. Rohde, I. Raz. New England Journal of Medicine, 2001

5,870 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Nephrology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/29ca3f90124d6ba17c00bd2607aa6a096284ae53

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Giuseppe Remuzzi
2. J. Forbes
3. M. Cooper
4. S. Laurent
5. Paulus Kirchhof
6. Daniel W. Jones
7. J. Wright
8. E. Schiffrin

In Nephrology

1. Youhua Liu
2. Marcello Tonelli
3. Tom Greene
4. W. Mitch
5. Giuseppe Remuzzi
6. Nur Samsu
7. V. Basevi

In Pulmonary and Respiratory Medicine

1. M. Cooper
2. J. Forbes
3. Youhua Liu

Citations in the corpus

• An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines (2020, methodology): “73 m(2)/year in the irbesartan-treated group.(65) Similarly, in the losartan arm of the Reduction of End Points in NIDDM with the Angiotensin II Receptor Antagonist Losartan (RENAAL) trial, the average change in eGFR was −4.”
• Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. (2004, background): “For instance, pharmacologic inhibition of the activities of AngII has been proven to be effective in the treatments of the patients with chronic renal insufficiency (5,6).”